Article Text
PDFFeatured editorial
More about the “ARB MI paradox”
Abstract
“Logic dictates that angiotensin converting enzyme inhibitors should remain the preferred drug across the entire spectrum of cardiometabolic disease”
- ACEi, angiotensin converting enzyme inhibitors
- ARB, angiotensin receptor blocker
- CV, cardiovascular
- MI, myocardial infarction
- angiotensin
- antagonist
- infarction
- myocardial
- receptor